General
Preferred name
JNJ-40346527
Synonyms
JNJ-527 ()
edicotinib ()
Edicotinib(JNJ-40346527) ()
EDICOTINIB HYDROCHLORIDE ()
JNJ-40346527 HCI ()
JNJ-40346527-AAC ()
P&D ID
PD046694
CAS
1142363-52-7
Tags
available
drug candidate
Drug indication
Rheumatoid arthritis
Hodgkin lymphoma
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION JNJ-40346527 was identified in a medicinal-chemistry lead optimization study to develop oral, selective CSF1R kinase inhibitors. JNJ-40346527 is compound I-S in patent US20140045789 . PubChem CID 25230468 is a tautomer which is also covered by the patent. Clinical development of JNJ-40346527 was terminated in 2014 due to a lack of efficacy.
DESCRIPTION JNJ-40346527 was identified in a medicinal-chemistry lead optimization study to develop oral, selective CSF1R kinase inhibitors. JNJ-40346527 is compound I-S in patent US20140045789 . PubChem CID 25230468 is a tautomer which is also claimed in the patent. Clinical development of JNJ-40346527 was terminated in 2014 due to a lack of efficacy.
DESCRIPTION Edicotinib (PRV-6527; previously JNJ-40346527) was identified in a medicinal-chemistry lead optimization study to develop oral, selective CSF1R kinase inhibitors. The chemical structure is compound I-S in patent US20140045789 . PubChem CID 25230468 is a tautomer which is also claimed in the patent. (GtoPdb)
DESCRIPTION Edicotinib (JNJ-40346527) is a potent, selective, brain penetrant and orally active colony-stimulating factor-1 receptor (CSF-1R) inhibitor with an IC50 of 3.2 nM. Edicotinib exhibits less inhibitory effects on KIT and FLT3 with IC50 values of 20 nM and 190 nM, respectively[1]. Edicotinib limits microglial expansion and attenuates microglial proliferation and neurodegeneration in mice. Edicotinib has the potential for Alzheimer¡¯s disease and rheumatoid arthritis research[1][2].
PRICE 216
DESCRIPTION Edicotinib (JNJ-527) is a blood-brain-penetrating, orally active, selective CSF-1R inhibitor (IC50 value is 3.2 nM), with less inhibitory effects on KIT (IC50 value is 20 nM) and FLT3 (IC50 value is 190 nM). Edicotinib (JNJ-527) can block microglial proliferation and attenuate neurodegeneration, and can be used to study Alzheimer's disease and rheumatoid arthritis. (TargetMol Bioactive Compound Library)
Compound Sets
11
Cayman Chemical Bioactives
33347
ChEMBL Drugs
CHEMBL3674570
CHEMBL4297225
DrugBank
DB12504
DrugMAP
DM219SF
EU-OPENSCREEN Bioactive Compound Library
EOS101336
Guide to Pharmacology
8942
MedChem Express Bioactive Compound Library
HY-109086
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
edicotinib
TargetMol Bioactive Compound Library
T15199
External IDs
25
Properties
(calculated by RDKit )
Molecular Weight
461.28
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
2
cLogP
5.97
TPSA
103.69
Fraction CSP3
0.56
Chiral centers
0.0
Largest ring
6.0
QED
0.58
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
c-Fms
CSF-1R
FLT3
KIT
Pathway
Angiogenesis
Tyrosine Kinase/Adaptors
Protein Tyrosine Kinase/RTK
Source data